New hope for frail cancer patients: enhertu trial targets Tough-to-Treat stomach and esophageal tumors
NCT ID NCT07126561
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests the drug Enhertu in 43 people with newly diagnosed HER2-positive stomach, esophageal, or gastroesophageal junction cancer that has spread. Participants have a lower physical ability (ECOG 2) and will receive Enhertu by IV every 3 weeks. The main goal is to see how many patients' tumors shrink, while also monitoring side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2 POSITIVE NEWLY DIAGNOSED METASTATIC ESOPHAGEAL, GASTRIC, GEJ CANCER PATIENTS WITH AN ECOG PERFORMANCE STATUS OF 2 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••